Abstract
Ibandronate is a potent nitrogen-containing bisphosphonate and is a convenient therapeutic drug for osteoporosis because ibandronate can be administrated once a month or at much longer interval by orally or intravenously (bolus injection). In BONE study, that is a large-scale pivotal study on fracture with osteoporosis patients, efficacy to prevent the incidence of new vertebral fracture was shown in both regimen of 2.5 mg daily and 20 mg intermittent oral administration. Then the clinical development by new intermittent dosing method was accelerated, aiming at the improvement of compliance/adherence which is one of the issues when the bisphosphonates are administered orally. Both monthly oral and quarterly intravenous bolus injectable formulations of ibandronate for osteoporosis already have been launched in the U.S., EU and other countries. In parallel, both formulations for osteoporosis have being also developed in Japan. We expect ibandronate will provide a new option for the treatment of osteoporosis in Japan.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
